📋 Tender Overview
Contract awarded for Centralized framework agreement for 24 months for the supply of medicines iii/2026 { "detected_language": "romanian", "translated_text": "lot-0036, title: betaderm ® or equivalent, description: the product description, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0054, title: captopril 25 mg ®, captopril lph 25 mg ® or equivalent, description: the product description, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0089, title: diltiazem 60 mg ® or equivalent, description: the product description, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0114, title: esomeprazole -40mg- powder for solution for injection/perfusion or equivalent, description: the product description, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0133, title: furosemide 40 mg ® or equivalent, description: the product description, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0137, title: gentamicin sulphate ® or equivalent, description: the product description, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0148, title: sodium hydrocortisone succinate 100 mg ® or equivalent, description: the product description, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0156, title: indomethacin 50 mg ® or equivalent, description: the product description, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0180, title: ketanov 30 mg/ml ® or equivalent, description: the product description, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0186, title: colospasmin ® or equivalent, description: the product description, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0191, title: xefo rapid 8 mg ® or equivalent, description: the product description, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0201, title: meloxicam rompharm 15 mg/1.5 ml ® or equivalent, description: the product description, the minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0212, estimated value excluding vat: 44422.00 ron.Centralized framework agreement for 24 months for the supply of medicines iii/2026
